Jitka Yehudith Sagiv

Vyne Therapeutics (Israel) — Israel

Biochemistry, Genetics and Molecular Biology · Life Sciences

6h-index1.1kcitations30works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Diabetes and associated disorders(18), Atherosclerosis and Cardiovascular Diseases(16), Immune Response and Inflammation(11), Immunotherapy and Immune Responses(5), Immune cells in cancer(5)

Publications30 total

246 AI-designed immune sensor-enhanced CAR-T cells for potent solid tumor immunotherapy
Regular and Young Investigator Award Abstracts·2025Open Access
408 Establishing a tumor cell derived immune response, reprogramming the tumor microenvironment from within
Regular and Young Investigator Award Abstracts·2024Open Access
1217 Triggering immune response from within cancer cells
Regular and Young Investigator Award Abstracts·2023Open Access
Figure S7 from Toxicology and Pharmacokinetic Studies in Mice and Nonhuman Primates of the Nontoxic, Efficient, Targeted Hexameric FasL: CTLA4-FasL
2023Open Access
Table S1, S2 from Toxicology and Pharmacokinetic Studies in Mice and Nonhuman Primates of the Nontoxic, Efficient, Targeted Hexameric FasL: CTLA4-FasL
2023Open Access
Data from Toxicology and Pharmacokinetic Studies in Mice and Nonhuman Primates of the Nontoxic, Efficient, Targeted Hexameric FasL: CTLA4-FasL
2023Open Access
Figure S6 from Toxicology and Pharmacokinetic Studies in Mice and Nonhuman Primates of the Nontoxic, Efficient, Targeted Hexameric FasL: CTLA4-FasL
2023Open Access
Figure S2 from Toxicology and Pharmacokinetic Studies in Mice and Nonhuman Primates of the Nontoxic, Efficient, Targeted Hexameric FasL: CTLA4-FasL
2023Open Access
Figure S1 from Toxicology and Pharmacokinetic Studies in Mice and Nonhuman Primates of the Nontoxic, Efficient, Targeted Hexameric FasL: CTLA4-FasL
2023Open Access
Figure S4 from Toxicology and Pharmacokinetic Studies in Mice and Nonhuman Primates of the Nontoxic, Efficient, Targeted Hexameric FasL: CTLA4-FasL
2023Open Access
Figure S3 from Toxicology and Pharmacokinetic Studies in Mice and Nonhuman Primates of the Nontoxic, Efficient, Targeted Hexameric FasL: CTLA4-FasL
2023Open Access
Figure S7 from Toxicology and Pharmacokinetic Studies in Mice and Nonhuman Primates of the Nontoxic, Efficient, Targeted Hexameric FasL: CTLA4-FasL
2023Open Access
Figure S5 from Toxicology and Pharmacokinetic Studies in Mice and Nonhuman Primates of the Nontoxic, Efficient, Targeted Hexameric FasL: CTLA4-FasL
2023Open Access
Supplementary Methods from Toxicology and Pharmacokinetic Studies in Mice and Nonhuman Primates of the Nontoxic, Efficient, Targeted Hexameric FasL: CTLA4-FasL
2023Open Access
Table S1, S2 from Toxicology and Pharmacokinetic Studies in Mice and Nonhuman Primates of the Nontoxic, Efficient, Targeted Hexameric FasL: CTLA4-FasL
2023Open Access
Data from Toxicology and Pharmacokinetic Studies in Mice and Nonhuman Primates of the Nontoxic, Efficient, Targeted Hexameric FasL: CTLA4-FasL
2023Open Access
Figure S5 from Toxicology and Pharmacokinetic Studies in Mice and Nonhuman Primates of the Nontoxic, Efficient, Targeted Hexameric FasL: CTLA4-FasL
2023Open Access
Figure S4 from Toxicology and Pharmacokinetic Studies in Mice and Nonhuman Primates of the Nontoxic, Efficient, Targeted Hexameric FasL: CTLA4-FasL
2023Open Access
Figure S2 from Toxicology and Pharmacokinetic Studies in Mice and Nonhuman Primates of the Nontoxic, Efficient, Targeted Hexameric FasL: CTLA4-FasL
2023Open Access
Figure S1 from Toxicology and Pharmacokinetic Studies in Mice and Nonhuman Primates of the Nontoxic, Efficient, Targeted Hexameric FasL: CTLA4-FasL
2023Open Access
page 1 of 2Next →

Frequent Co-authors

Efi Makdasi(21), Shira Amsili(21), Alexandra Aronin(21), Tatyana B. Prigozhina(21), Kobi Tzdaka(21), Yosi Gozlan(21), Liat Ben Gigi–Tamir(21), Fanny Shkedy(21), Noam Shani(21), Mark L. Tykocinski(21), Michal Dranitzki Elhalel(21), Zvi Granot(5), Ronit Vogt Sionov(4), Simaan Assi(3), Inbal Mishalian(3), Lola Polyansky(3), Maya Gershkovitz(3), Assaf Marcus(3), Ofer Levy(3), Dor Shimon(3)